TCGA-55-7726-01A-11R-2170-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- ANGIOGENESIS+0.570
- TGF_BETA_SIGNALING+0.520
- UV_RESPONSE_DN+0.460
- KRAS_SIGNALING_UP+0.440
- NOTCH_SIGNALING+0.420
- G2M_CHECKPOINT+0.370
- HEDGEHOG_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- FATTY_ACID_METABOLISM-0.370
- MYC_TARGETS_V2-0.340
- PEROXISOME-0.340
- INTERFERON_ALPHA_RESPONSE-0.300
- ADIPOGENESIS-0.290
- CHOLESTEROL_HOMEOSTASIS-0.270
- DNA_REPAIR-0.270
- BILE_ACID_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.881 |
| 2 | DRR168609 | — | — | 0.874 |
| 3 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.856 |
| 4 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.842 |
| 5 | SAMN03290934 | — | — | 0.837 |
| 6 | SRR25043621 | — | — | 0.832 |
| 7 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.831 |
| 8 | BS_MKM0EEN1 | Diffuse intrinsic pontine glioma | — | 0.826 |
| 9 | TCGA-AR-A24P-01A-11R-A169-07 | — | A | 0.818 |
| 10 | TCGA-44-8119-01A-11R-2241-07 | — | cohortA3 | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.570 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.520 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |